Phase III Data For La Jolla's Angiotensin II Drug Leave Questions About Clinical Benefit
La Jolla's LJPC-501 meets primary blood pressure endpoint in the Phase III ATHOS-3 vasodilatory shock trial, but data suggest benefits may not translate into clinically meaningful improvements.